Skip to main content
Clinical Trials/RBR-7tdjcn5
RBR-7tdjcn5
Active, Not Recruiting
N/A

Efficacy and safety of using Botulinum Toxin type A in the Masseter Hypertrophy treatment

Faculdade Ingá - UNINGÁ/Paraná0 sitesJanuary 24, 2024

Overview

Phase
N/A
Intervention
Not specified
Conditions
Masseter muscle
Sponsor
Faculdade Ingá - UNINGÁ/Paraná
Status
Active, Not Recruiting
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
January 24, 2024
End Date
October 15, 2023
Last Updated
2 years ago
Study Type
Intervention
Sex
Female

Investigators

Sponsor
Faculdade Ingá - UNINGÁ/Paraná

Eligibility Criteria

Inclusion Criteria

  • Female patients; age between 25 and 50 years; complaining of enlargement of the lower third of the face; complaining of unilateral or bilateral hypertrophy of the masseter muscle; have not received aesthetic procedures on the lower third of the face in the last 12 months

Exclusion Criteria

  • Having received an anti\-tetanus or COVID\-19 vaccine within a period of less than three months, before starting the research; having previously received injections of botulinum toxin for aesthetic or therapeutic purposes; presenting autoimmune diseases; pregnant and lactating women; present neuromuscular diseases (Myasthenia gravis and Lambert\-Eaton Syndrome); in current use of drugs that act on neuromuscular junctions; having performed cosmetic surgeries on the lower third of the face; missing teeth; individuals under 25 years of age; those who do not agree to sign the Free and Informed Consent Form; those who receive some type of vaccine during the research; received aesthetic procedures in the lower third of the face in the last 12 months

Outcomes

Primary Outcomes

Not specified

Similar Trials